شركة أستيللاس تتولى بيع “كادويت – فايزر” في اليابان

Pfizer and Astellas announced change to their Japanese co-promotion deal for the hypertension drug Caduet (amlodipine/atorvastatin), giving the latter sole distribution rights in the country beginning in October. Astellas will now book sales currently recorded by Pfizer, the holder of marketing rights in Japan. Astellas noted that the affect of the amended deal on its financial forecast for the current year “will be immaterial.”

In January, Pfizer settled a US patent dispute, allowing Mylan to begin marketing a generic version of Caduet starting November 30 or earlier under certain circumstances.